mayo clinic bpc 157 Peptides are all the rage, but proceed with caution BPC - 157 | ELIXR

By choosing Endogenic, you are choosing effectiveness and quality

Lancet Oncol 15(6):569579 Thatcher N et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

A batch-specific CoA belongs to exactly the batch you receive with batch number, date and purity value, issued by an independent laboratory (Janoshik and similar are the industry standard)

We believe in giving our patients real options that support healing at the root level, not just masking symptoms